Latest Regulatory Approvals News

Bass Oil reported steady oil production and a significant cash reserve increase in the June quarter, while strategically acquiring the Vanessa gas field to pivot towards gas production.

CurveBeam AI reported a strong Q4 FY25 with record customer receipts and an 18% rise in purchase orders, while advancing key regulatory milestones and securing a major financing facility.

Critica Limited reports significant progress on its Jupiter Rare Earths Project, unveiling a 95% mass reduction in beneficiation testwork and appointing a new CEO to drive development.

Javelin Minerals reports a significant 27% increase in indicated gold resources at its Eureka project, advancing plans for mining and early cash flow amid strong drilling results.

Impact Minerals reports a robust Preliminary Feasibility Study for its Lake Hope High Purity Alumina project, underpinned by strong economics and low production costs, while strategically acquiring a 50% stake in Alluminous Pty Ltd to fast-track market entry with HiPurA® technology.

TG Metals Limited has confirmed promising gold grades from drilling at the Van Uden Project’s historical stockpiles, paving the way for imminent processing and near-term cash flow generation.

QPM Energy has launched its Isaac Energy Hub and completed a major overhaul of the Townsville Power Station, setting the stage for a final investment decision on its Isaac Power Station by year-end.

Netlinkz Limited reported $979,000 in quarterly receipts and a landmark $1 million VSN license sale in the Philippines, while advancing significant cost reductions and debt restructuring efforts.

Viridis Mining and Minerals has raised AU$11.5 million through a heavily oversubscribed placement, strengthening its balance sheet to advance the Colossus Rare Earth Project towards Final Investment Decision. The funding, backed by institutional and strategic Brazilian partners, positions Viridis with nearly AU$58.5 million in cash to accelerate development and regulatory approvals.

Neurizon Therapeutics has made significant strides in developing its lead ALS drug candidate NUZ-001, unveiling a new liquid formulation and submitting a key regulatory response to the FDA. Clinical and preclinical data bolster hopes for broader neurodegenerative applications.

Actinogen Medical has reached a key milestone in its XanaMIA phase 2b/3 Alzheimer’s trial with over 100 participants enrolled, setting the stage for an interim analysis in January 2026. The company also secured a $13.8 million non-dilutive R&D funding facility to support ongoing development.

Avecho Biotechnology has ramped up recruitment in its pivotal Phase III insomnia trial and is advancing plans for regulatory approval and commercialization of its TPM®-enhanced CBD capsule, aiming to be the first over-the-counter CBD insomnia treatment in Australia.